Kestra Medical Technologies (KMTS) EBITDA (2024 - 2026)

Kestra Medical Technologies (KMTS) has 3 years of EBITDA data on file, last reported at -$34.8 million in Q1 2026.

• EBITDA for Q1 2026 came in at -$34.8 million, down 68.75% year-over-year; the trailing twelve-month figure through Jan 2026 was -$143.6 million (down 82.91% YoY), and the FY2025 annual result was -$106.4 million, down 25.06% from the prior year.
• EBITDA fell to -$34.8 million in Q1 2026 per KMTS's latest filing, from -$31.8 million in the prior quarter.
• Over five years, EBITDA peaked at -$18.4 million in Q3 2024 and troughed at -$48.2 million in Q2 2025.
• A 3-year average of -$26.9 million and a median of -$20.6 million in 2025 frame the typical range for EBITDA.
• On a YoY basis, EBITDA climbed as much as 3.28% in 2025 and fell as far as 136.93% in 2025.
• A 3-year view of EBITDA shows it stood at -$19.1 million in 2024, then sank by 65.96% to -$31.8 million in 2025, then dropped by 9.48% to -$34.8 million in 2026.
• Business Quant data shows KMTS's EBITDA at -$34.8 million in Q1 2026, -$31.8 million in Q4 2025, and -$28.9 million in Q3 2025.